10.2021

October 6, 2021
|In Portfolio news
|By Ventac Partners

Ventac portfolio company RhoVac AB report positive 3-year follow-up results from a Phase I/IIa study in prostate cancer. The company is a clinical stage Swedish immunotherapy company developing RhoC-targeted therapies to treat cancer. For more information, please follow this link.